Literature DB >> 8485017

A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects.

D L Murdoch1, G Forrest, D L Davies, G T McInnes.   

Abstract

1. The relative potencies of amiloride (5 and 20 mg) and spironolactone (25 and 100 mg) for plasma and erythrocyte electrolytes were investigated in a double-blind, randomised, balanced, crossover study in 12 normal men treated concomitantly with hydrochlorothiazide 100 mg daily for 1 week. 2. Participants satisfied an a priori requirement for a fall in plasma potassium concentration of at least 0.5 mmol l-1 after 7 days of treatment with hydrochlorothiazide alone. 3. After hydrochlorothiazide alone, plasma potassium and sodium concentrations fell (P < 0.001). There were associated reductions in erythrocyte sodium (P < 0.01). Plasma magnesium concentration did not change, although erythrocyte magnesium decreased (P < 0.001). 4. Both amiloride and spironolactone attenuated the thiazide-induced fall in plasma potassium (relative potency, amiloride:spironolactone 10:1, 95% confidence interval 6.3-16.2:1). Amiloride but not spironolactone was associated with a dose-related increase in plasma magnesium; a relative potency estimation was precluded. There was little evidence of influences of amiloride or spironolactone on erythrocyte electrolytes. 5. On a weight basis, amiloride is ten times more potent than spironolactone as a potassium-sparing agent in diuretic-treated subjects but neither agent had major effects on erythrocyte potassium. The drugs may have divergent actions on magnesium handling; hydrochlorothiazide alone had no influence on plasma magnesium.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485017      PMCID: PMC1381547          DOI: 10.1111/j.1365-2125.1993.tb04153.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  MAGNESIUM METABOLISM IN HYPERTENSION.

Authors:  R H SELLER; O RAMIREZ-MUXO; A N BREST; J H MOYER
Journal:  JAMA       Date:  1965-02-22       Impact factor: 56.272

2.  Observations in experimental magnesium depletion.

Authors:  R WHANG; L G WELT
Journal:  J Clin Invest       Date:  1963-03       Impact factor: 14.808

3.  Plasma and muscle electrolytes in patients receiving diuretics. Methodological and clinical considerations.

Authors:  J Bergström
Journal:  Acta Cardiol       Date:  1973       Impact factor: 1.718

4.  Comparison of the potassium- retaining effects of amiloride and spironolactone in hypertensive patients with thiazide-induced hypokalaemia.

Authors:  C F George; A M Breckenridge; C T Dollery
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

Review 5.  Some aspects of the interrlationship of magnesium and potassium.

Authors:  R Whang
Journal:  J Chronic Dis       Date:  1968-07

6.  Amiloride. A potassium-sparing natriuretic agent.

Authors:  M B Bull; J H Laragh
Journal:  Circulation       Date:  1968-01       Impact factor: 29.690

7.  The acute effects of mersalyl, chlorothiazide and mannitol on the renal excretion of calcium and other ions in man.

Authors:  A M Parfitt
Journal:  Clin Sci       Date:  1969-04       Impact factor: 6.124

8.  Adequacy of twice daily dosing with potassium chloride and spironolactone in thiazide treated hypertensive patients.

Authors:  J M Toner; L A Brawn; W W Yeo; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

9.  Thiazide treatment of systemic hypertension: effects on serum magnesium and ventricular ectopic activity.

Authors:  J W Hollifield
Journal:  Am J Cardiol       Date:  1989-04-18       Impact factor: 2.778

10.  Magnesium deficiency in patients on long-term diuretic therapy for heart failure.

Authors:  P Lim; E Jacob
Journal:  Br Med J       Date:  1972-09-09
View more
  8 in total

1.  Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent.

Authors:  Anne Blanchard; Michael Frank; Grégoire Wuerzner; Severine Peyrard; Lise Bankir; Xavier Jeunemaitre; Michel Azizi
Journal:  Clin J Am Soc Nephrol       Date:  2011-01-13       Impact factor: 8.237

Review 2.  Renal Toxicities of Targeted Therapies.

Authors:  Anum Abbas; Mohsin M Mirza; Apar Kishor Ganti; Ketki Tendulkar
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

3.  What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?

Authors:  Domenic A Sica
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

4.  Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome.

Authors:  Anne Blanchard; Rosa Vargas-Poussou; Marion Vallet; Aurore Caumont-Prim; Julien Allard; Estelle Desport; Laurence Dubourg; Matthieu Monge; Damien Bergerot; Stéphanie Baron; Marie Essig; Frank Bridoux; Ivan Tack; Michel Azizi
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

5.  Treatment considerations with aldosterone receptor antagonists.

Authors:  Domenic A Sica; John M Flack
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-10-04       Impact factor: 3.738

6.  Hypomagnesemia and functional hypoparathyroidism due to novel mutations in the Mg-channel TRPM6.

Authors:  Marianne C Astor; Kristian Løvås; Anette S B Wolff; Bjørn Nedrebø; Eirik Bratland; Jon Steen-Johnsen; Eystein S Husebye
Journal:  Endocr Connect       Date:  2015-08-13       Impact factor: 3.335

7.  Sodium and magnesium in the distal convoluted tubule: no longer a couple?

Authors:  Aylin R Rodan
Journal:  Physiol Rep       Date:  2018-07

Review 8.  Molecular Mechanisms of Renal Magnesium Reabsorption.

Authors:  David H Ellison; Yujiro Maeoka; James A McCormick
Journal:  J Am Soc Nephrol       Date:  2021-05-27       Impact factor: 14.978

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.